Research News
SELECT found fewer cardiovascular events with semaglutide 2.4 mg. The population was narrow.
In adults with cardiovascular disease and overweight or obesity, and without diabetes, weekly semaglutide 2.4 mg…
Archive
Month: September 2026
Recently Published Studies
SURMOUNT-2 measured tirzepatide in adults who had both obesity and type 2 diabetes
Over 72 weeks, weekly tirzepatide 10 mg and 15 mg produced larger mean weight reductions than…
Research News
FLOW tested semaglutide 1 mg in diabetic kidney disease, not the obesity dose
Perkovic and colleagues reported fewer major kidney-disease events with weekly semaglutide 1 mg in adults who…
Research Paper Reviews
A close reading of SELECT: the hazard ratio and the people who stopped
The cardiovascular benefit and the discontinuation rate are in the same paper. Quoting one without the…
Preclinical Research
A rat wound study of thymosin beta-4 is still a rat wound study
Malinda and colleagues reported faster re-epithelialization in a full-thickness rat model. The peptide in the paper…
Emerging Molecules
Semaglutide is one molecule and at least two evidence files
SELECT used 2.4 mg weekly in people without diabetes. FLOW used 1 mg weekly in people…
Research Commentary
A healing paper is not a reason to buy a vial
The fastest way to wreck a research journal is to end every preclinical summary with a…
Research Commentary
A hazard ratio without its population is not a finding
SELECT and FLOW both report hazard ratios below 1 for semaglutide. They enrolled different people, at…
Research Methods
Read the dose before you repeat the hazard ratio
A methods note on two semaglutide trials: 2.4 mg and 1 mg were different assignments, so…
Emerging Molecules
Adding type 2 diabetes changes the tirzepatide weight percentage
SURMOUNT-2, in adults with obesity and type 2 diabetes, did not reproduce the weight change reported…
Research Commentary
Vendor codes are not the names of the trials
GLP1-SG, GLP2-TZ, and GLP3-RT are catalog shorthand. STEP 1, SURMOUNT-1, and the retatrutide phase 2 used…
Industry/Regulatory Developments
The approved afamelanotide product is a 16 mg implant called Scenesse
FDA approved Scenesse in 2019 for adults with erythropoietic protoporphyria. The label describes an implant given…